Literature DB >> 6999849

Benzbromarone as a long-term uricosuric agent.

R Bluestone, J Klinenberg, I K Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6999849     DOI： 10.1007/978-1-4615-9140-5_46

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  4 in total

Review 1.  Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?

Authors:  Ted R Mikuls; Kenneth G Saag
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

Review 2.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.

Authors:  Daniel Hill-McManus; Elena Soto; Scott Marshall; Steven Lane; Dyfrig Hughes
Journal:  Br J Clin Pharmacol       Date:  2017-10-10       Impact factor: 4.335

4.  Association Between Use of Anti-gout Preparations and Dementia: Nested Case-Control Nationwide Population-Based Cohort Study.

Authors:  Tsung-Ju Chuang; Yu-Hsun Wang; James Cheng-Chung Wei; Chih-Jung Yeh
Journal:  Front Med (Lausanne)       Date:  2021-01-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.